July 1 2021 | Targeted Therapies in Oncology

New Guidelines Divide Recommendations for Driver and Nondriver NSCLC

July 19, 2021

Clinical Articles

In 2017, the American Society of Clinical Oncology and the Ontario Health-Cancer Care Ontario's non–small cell lung cancer expert panel published a guideline with recommendations for systemic therapy for patients with stage IV NSCLC.

Clinical Pathways Expanded to Include Data Collection, EHR Management at Geisinger

July 17, 2021

Clinical Articles

Clinical pathways in cancer care are beyond the “new” phase, but oncology practices and health systems are still learning all the ways they can bring greater standardization to care, eliminate unnecessary care, improve data collection, and drive value.

Modernized Clinical Trials Include Diverse Representation, Decentralization, and Real-World Data in Post–COVID-19 Era

July 10, 2021

Clinical Articles

The rapid issuance of clinical trial guidance, trial modifications and emphasis on inclusivity of diverse racial and ethnic patient populations have opened the door for new opportunities for decentralized clinical trials and real-world data in a post-Covid-19 world

Triplet Regimen of Trastuzumab, Pertuzumab, and Paclitaxel Improves pCR, Survival in HER2+ Breast Cancer

July 07, 2021

Clinical Articles

Adding paclitaxel to the combination of trastuzumab and pertuzumab was associated with pathologic complete response and invasive disease-free survival in patients with HER2-positive breast cancer compared with the doublet alone.

Atezolizumab Plus Carboplatin Induces Early Efficacy Signals in Invasive Lobular Breast Cancer

July 06, 2021

Clinical Articles

Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression.